AngioLab, Inc.   Report issue

For profit Phase 2
Founded: Daejeon Korea, Republic of (1999)

Organization Overview

First Clinical Trial
2018
NCT03725501
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Alternative names

AngioLab, Inc.

Active Ingredients

Drugs in Phase 2 Trials (3)

als-l1023 (2 trials)

horse chestnut leaf extract (1 trial)

ranibizumab (lucentis) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Chronic Periodontitis (Phase 2)

Fatty Liver (Phase 2)

Macular Degeneration (Phase 2)

Non-alcoholic Fatty Liver Disease (Phase 2)

Periodontitis (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 3
  • # of Trial APIs: 3